These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24303922)

  • 1. Upregulation of S100P, receptor for advanced glycation end products and ezrin in malignant melanoma.
    Zhu L; Ito T; Nakahara T; Nagae K; Fuyuno Y; Nakao M; Akahoshi M; Nakagawa R; Tu Y; Uchi H; Furue M
    J Dermatol; 2013 Dec; 40(12):973-9. PubMed ID: 24303922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type.
    Aishima S; Fujita N; Mano Y; Kubo Y; Tanaka Y; Taketomi A; Shirabe K; Maehara Y; Oda Y
    Am J Surg Pathol; 2011 Apr; 35(4):590-8. PubMed ID: 21412073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional regulation and functional implication of S100P in cancer.
    Gibadulinova A; Tothova V; Pastorek J; Pastorekova S
    Amino Acids; 2011 Oct; 41(4):885-92. PubMed ID: 20155429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100P promotes pancreatic cancer growth, survival, and invasion.
    Arumugam T; Simeone DM; Van Golen K; Logsdon CD
    Clin Cancer Res; 2005 Aug; 11(15):5356-64. PubMed ID: 16061848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The S100P/RAGE signaling pathway regulates expression of microRNA-21 in colon cancer cells.
    Mercado-Pimentel ME; Onyeagucha BC; Li Q; Pimentel AC; Jandova J; Nelson MA
    FEBS Lett; 2015 Aug; 589(18):2388-93. PubMed ID: 26193421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways.
    Fuentes MK; Nigavekar SS; Arumugam T; Logsdon CD; Schmidt AM; Park JC; Huang EH
    Dis Colon Rectum; 2007 Aug; 50(8):1230-40. PubMed ID: 17587138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100P, a peculiar member of S100 family of calcium-binding proteins implicated in cancer.
    Tóthová V; Gibadulinová A
    Acta Virol; 2013; 57(2):238-46. PubMed ID: 23600880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE).
    Arumugam T; Simeone DM; Schmidt AM; Logsdon CD
    J Biol Chem; 2004 Feb; 279(7):5059-65. PubMed ID: 14617629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer.
    Onyeagucha BC; Mercado-Pimentel ME; Hutchison J; Flemington EK; Nelson MA
    Exp Cell Res; 2013 Aug; 319(13):2081-2090. PubMed ID: 23693020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100P and Ezrin promote trans-endothelial migration of triple negative breast cancer cells.
    Kikuchi K; McNamara KM; Miki Y; Iwabuchi E; Kanai A; Miyashita M; Ishida T; Sasano H
    Cell Oncol (Dordr); 2019 Feb; 42(1):67-80. PubMed ID: 30244410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium-binding protein S100P and cancer: mechanisms and clinical relevance.
    Jiang H; Hu H; Tong X; Jiang Q; Zhu H; Zhang S
    J Cancer Res Clin Oncol; 2012 Jan; 138(1):1-9. PubMed ID: 21947242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promotion of the occurrence of endometrioid carcinoma by S100 calcium binding protein P.
    Zhang D; Chen X; Xia H; Wang L; Zhao H; Xu B; Zhang A; Zhang W
    BMC Cancer; 2020 Sep; 20(1):845. PubMed ID: 32883230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S100P: a novel therapeutic target for cancer.
    Arumugam T; Logsdon CD
    Amino Acids; 2011 Oct; 41(4):893-9. PubMed ID: 20509035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and characterization of a novel, permanently active S100P mutant.
    Austermann J; Nazmi AR; Heil A; Fritz G; Kolinski M; Filipek S; Gerke V
    Biochim Biophys Acta; 2009 Jun; 1793(6):1078-85. PubMed ID: 19111582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis.
    Arumugam T; Ramachandran V; Gomez SB; Schmidt AM; Logsdon CD
    Clin Cancer Res; 2012 Aug; 18(16):4356-64. PubMed ID: 22718861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P.
    Koltzscher M; Neumann C; König S; Gerke V
    Mol Biol Cell; 2003 Jun; 14(6):2372-84. PubMed ID: 12808036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S100 to receptor for advanced glycation end-products binding assay: looking for inhibitors.
    Padilla L; Dakhel S; Hernández JL
    Biochem Biophys Res Commun; 2014 Mar; 446(1):404-9. PubMed ID: 24613850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insights into calcium-bound S100P and the V domain of the RAGE complex.
    Penumutchu SR; Chou RH; Yu C
    PLoS One; 2014; 9(8):e103947. PubMed ID: 25084534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The receptor for advanced glycation end products influences the expression of its S100 protein ligands in melanoma tumors.
    Meghnani V; Wagh A; Indurthi VS; Koladia M; Vetter SW; Law B; Leclerc E
    Int J Biochem Cell Biol; 2014 Dec; 57():54-62. PubMed ID: 25310905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
    Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
    Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.